Financials
Financials — Star Health and Allied Insurance Co. Ltd.
Star Health is India's largest standalone private health insurer (SAHI), collecting ₹18,622 crore in gross written premium in FY2026 — a 20.5% compound annual growth rate since FY2018 — with a 31% share of India's retail health insurance market. The business trades at 4.0× book value despite a statutory return on equity of roughly 7–9%, meaning the market is pricing in a significant ROE expansion to ~20% that has not yet materialised. The single financial metric that matters most right now is the combined ratio: every 100 basis points of improvement adds roughly ₹186 crore to pre-tax profit. The FY2026 trajectory (Q4 combined ratio 95.7%) is the most encouraging signal in years; whether it holds through the monsoon quarter will determine whether the bull case is achievable at the current valuation.
Accounting note. Star Health reports under two distinct bases: (1) statutory standalone, filed with SEBI — used throughout this page for historical consistency; (2) IndAS, used in management earnings communications. For FY2026, statutory PAT was ₹557 crore (−14% YoY) while IndAS PAT was ₹911 crore (+16% YoY on an IndAS-restated FY2025 base of ₹787 crore). The difference arises from mark-to-market investment accounting and long-term policy premium recognition. Analysts citing "16% PAT growth" use IndAS. Valuation multiples in this page use statutory EPS (₹9.47) and IndAS EPS (₹15.49) in parallel where relevant.
GWP FY2026 (₹ cr)
Statutory PAT FY2026 (₹ cr)
Combined Ratio (%)
Price / Book Value
Solvency Ratio (%)
1. Revenue, Margins, and Earnings Power
Star Health's economic engine has three components: (1) premium underwriting — collect premiums, pay claims and expenses; (2) investment float — policyholder premiums sit in an ₹17,898 crore investment portfolio earning ~7.8% annually; (3) scale leverage — operating expenses grow slower than premiums over time. GWP has compounded at 20.5% annually since FY2018. The COVID years (FY2021–22) inflicted massive underwriting losses as combined ratios reached 122% and 118%, wiping out two years of equity. The recovery since FY2023 has been real but uneven: FY2024 was the strongest year post-COVID (combined ratio 97.3%, ROE 13.3%), FY2025 saw claims creep return the combined ratio to 101.1%, and FY2026 shows the clearest improvement with a full-year combined ratio of 98.8% and a Q4 reading of 95.7%.
GWP grew 11% YoY to ₹18,622 crore on the statutory basis (16% on the N-basis management figure of ₹20,369 crore). The gap exists because the N-basis does not apply the 1/N spreading adjustment for long-term policies sold in the period. Retail health, which accounts for ~95% of GWP, grew 20% on the N-basis to ₹19,341 crore. The statutory PAT of ₹557 crore fell 14% from ₹646 crore in FY2025. This paradox — revenue growing 11% while profit fell 14% — is largely an accounting artefact of MTM investment losses under statutory rules; on IndAS, PAT rose 16% to ₹911 crore and management reported a swing to underwriting profit of ₹206 crore (from an underwriting loss of ₹165 crore in FY2025).
The combined ratio — the sum of the loss ratio (claims / net premiums) and expense ratio (commissions + expenses / premiums) — is the central metric for an insurer's underwriting health. A combined ratio below 100% means the company profits from insurance alone; above 100% means underwriting loses money and the business relies on investment income. FY2021–22 combined ratios of 122% and 118% were catastrophically high during COVID. FY2024's 97.3% was the post-COVID best. FY2026's 98.8% with a Q4 reading of 95.7% is a promising inflection, driven by loss ratio improvement to 68.7% (down 194 basis points) and expense ratio improvement to 30.1% (down 31 basis points).
The quarterly progression from Q1 FY2026 (102.1%) to Q4 FY2026 (95.7%) shows consistent improvement across three consecutive quarters. Q1 of each fiscal year is typically the weakest quarter (annual renewals coincide with claim-heavy first half). The acid test is whether Q1 FY2027 holds near 100% rather than reverting to the 102% pattern seen in prior years.
2. Cash Flow and Earnings Quality
Star Health is an insurance company, not a manufacturing business. The relevant "cash generation" concept is:
- Policyholder float: premiums are collected before claims are paid, creating a temporary cash float. Star Health's policyholder fund was ₹9,960 crore at FY2025. This float is invested in bonds and equities.
- Underwriting cash flow: when the combined ratio is below 100%, underwriting itself generates net cash. When above 100%, the insurer effectively pays out more in claims and expenses than it collects in premiums.
- Investment income: the float earns a return — ₹766 crore in FY2025 on a ₹17,898 crore portfolio at 7.79% yield.
No traditional free cash flow statement is available for Star Health, which is common for Indian insurers filing under statutory accounting. Earnings quality is best assessed by asking whether investment income supports reported profits or whether underwriting is doing the heavy lifting.
Investment income has grown from ₹89 crore in FY2018 to ₹766 crore in FY2025 — an 8.6× increase over seven years — as the float grew in lockstep with premium growth. The investment yield has been remarkably stable at 7–8%, consistent with a predominantly fixed-income portfolio invested in Indian government securities and high-grade bonds. This predictability is a quality signal: investment income is not driven by equity windfalls or mark-to-market gains in the income line; it is steady coupon income.
Earnings quality verdict: FY2025 and FY2026 profitability depends materially on investment income (₹766 crore in FY2025, roughly 119% of statutory net income). When the combined ratio is above 100%, the business is essentially an investment company that writes insurance to accumulate investable float. For the equity story to work at current valuation levels, underwriting needs to be consistently profitable — which the Q4 FY2026 combined ratio of 95.7% suggests is achievable, but not yet confirmed as durable.
FY2026 statutory PAT of ₹557 crore fell 14% YoY despite a better combined ratio, primarily due to mark-to-market losses on the investment portfolio under statutory accounting rules. On IndAS accounting — which better reflects economic investment returns — PAT was ₹911 crore (+16% YoY). Investors should monitor both to distinguish investment noise from operating signal.
3. Balance Sheet and Financial Resilience
For an insurer, balance sheet resilience means: (1) adequate solvency (equity capital relative to risk exposure); (2) investment portfolio quality (the float is matched to future claim liabilities); and (3) absence of financial leverage (debt that could destabilise operations).
Total assets have grown from ₹3,347 crore in FY2018 to ₹20,785 crore in FY2025, with the investment portfolio now accounting for 86% of total assets (₹17,898 crore of ₹20,785 crore). This is the correct shape for a health insurer — most assets should be invested float, not fixed assets or receivables. Equity has grown from ₹960 crore to ₹7,022 crore (FY2025) and further to ₹7,589 crore in FY2026.
Solvency Ratio FY2026 (%)
Debt / Equity Ratio
Net Worth FY2026 (₹ cr)
Book Value / Share (₹)
Solvency ratio measures an insurer's capital adequacy: how much net qualifying capital the insurer holds relative to its required solvency margin (risk-based minimum capital). IRDAI mandates a minimum of 150%. Star Health's solvency ratio stood at 1.67× (167%) at the FY2022 COVID trough — dangerously close to the regulatory minimum. By FY2026, it has recovered to 205%, reflecting equity capital rebuilding from profitable operations. This is a meaningful improvement, though not as strong as peers with consistently high ROEs.
The debt/equity ratio of 0.06× confirms Star Health is effectively debt-free. The "debt" represents minor operational borrowings or subordinated instruments, not financial leverage. This is appropriate for an insurer where policyholder liabilities already provide significant effective leverage.
Investment portfolio quality: The 7.79% yield on a predominantly fixed-income portfolio held at or near Indian government bond rates signals conservative, matched-book management. There is no material duration mismatch risk evident in the financials.
4. Returns, Reinvestment, and Capital Allocation
For an insurer, ROE is the primary capital efficiency metric. Decomposing ROE:
- ROE = net margin on GWP × GWP / equity
- Or equivalently: ROE = (combined ratio improvement leverage) × (float leverage) × investment yield
ROE collapsed to −23% in FY2022 (COVID claims catastrophe) and recovered to 13.3% in FY2024 — a genuine earnings inflection. The FY2025 retreat to 9.2% and the FY2026 statutory ROE of approximately 7.6% (₹557 crore PAT on average equity of ~₹7,300 crore) is a concerning trend. On the IndAS basis, FY2026 ROE is approximately 12.5% (₹911 crore / ~₹7,300 crore average equity), which is closer to the FY2024 peak.
Book value per share has grown steadily from ₹21 (FY2018) to ₹129 (FY2026 estimated), a 6.1× increase over eight years and roughly a 25% CAGR. This compounding of book value is the most consistent positive in the financial history. Even through the COVID loss years (FY2021–22), book value grew because the company raised equity capital to fund the losses, preserving solvency.
Capital allocation: Star Health retains virtually all earnings (payout ratio effectively 0%) and reinvests for growth. There are no significant share buybacks or special dividends. The paid-up capital grew modestly from ₹5,876 crore (FY2024) to ₹5,878 crore (FY2025), indicating minimal equity dilution. The capital allocation story is straightforward: grow premium volume, invest the float, and reinvest retained earnings to build the balance sheet. The question is whether the reinvestment rate earns above the cost of equity — which requires ROE sustainably above ~12–14% (our estimate of Ke for an Indian insurer). FY2024 (ROE 13.3%) achieved this; FY2025 and FY2026 did not on the statutory basis.
5. Segment and Unit Economics
Star Health operates almost entirely in retail health insurance. Retail health GWP was ₹19,341 crore on the N-basis in FY2026 (94.9% of total GWP). Group health and other segments account for the remaining ~5%. No granular profit-by-segment data is filed in the public statutory accounts; the segment breakdown below is based on premium volume only.
The retail health focus is both a strength and a constraint. Retail health is structurally higher-margin than group health (group is typically priced thin for employer-client retention). Star Health's retail loss ratio of 68.2% in FY2026 is better than the blended 68.7%, consistent with this premium mix advantage. The concentration risk, however, means every macroeconomic or regulatory shock to retail health directly hits the entire business.
Key unit economics:
- Retail health market share: 31% of India's retail health insurance market (FY2026)
- Renewal persistency: 99% (FY2026) — extremely high, indicating strong policyholder loyalty
- Digital channel: ~20% of fresh retail sales in FY2026
- Claims settled: ~30 lakh claims totalling ₹11,900+ crore in FY2026
6. Valuation and Market Expectations
The correct valuation framework for Star Health is price-to-book vs ROE. For an insurer, the justified P/B equals (ROE minus long-run growth) divided by (cost of equity minus long-run growth):
Justified P/B = (ROE − g) ÷ (Ke − g)
Assuming:
- Long-run GWP growth (g): 12–14% (India's health insurance market growing 15–20% with room for Star's market share to hold)
- Cost of equity (Ke): ~14% (Indian risk-free ~7%, equity premium ~6%, beta ~1.1)
| ROE Assumption | Justified P/B | Implied Price (on ₹129 BV) |
|---|---|---|
| 8% (bear: current statutory trend) | below 1× | less than ₹129 |
| 14% (base: recover to FY2024 level) | 1.0–2.0× | ₹129–260 |
| 18% (bull: scale efficiencies kick in) | 3.0× | ~₹390 |
| 21% (priced-in: today's P/B of 4×) | 4.0× | ~₹520 |
At ₹520, the market is pricing in a ~21% ROE scenario — roughly double current statutory levels and well above the FY2024 peak of 13.3%. The analyst consensus target of ₹587 (22 analysts, Buy rating) implies either more moderate P/B expansion on better ROE, or continued IndAS-basis premium. The scenario range spans ₹420 (bear: 8% ROE stagnation) to ₹700 (bull: 18%+ ROE achieved).
Historical valuation context: Star Health's IPO in December 2021 priced at ~₹906, implying a P/B of ~11× on the FY2022 book. The subsequent 43% decline to ₹520 represents material multiple compression as the market re-rated from speculative IPO excitement to a more realistic assessment of insurance economics. The IPO P/B of 11× was never defensible on fundamentals — it priced in the "only listed pure-play health insurer" scarcity premium.
Relative valuation: On a price-to-GWP basis, Star Health at 1.6× GWP trades cheaper than ICICI Lombard (~3.3× GWP) but higher than New India Assurance (~0.6×, PSU discount). The premium over state-owned peers is justified by superior growth and private-sector efficiency; the discount to ICICI Lombard reflects the fact that ICICI Lombard has diversified non-motor and health lines with historically higher ROE.
The margin of safety is narrow. At ₹520, the stock requires ~21% sustained ROE to justify its P/B multiple. Current statutory ROE of 7–9% creates a ~1,200 bps gap between reality and the price-implied expectation. The IndAS ROE of ~12.5% is closer but still does not justify a 4× P/B. Either strong ROE recovery (combined ratio sustainably near 95–97%) or multiple compression is the likely resolution.
7. Peer Financial Comparison
Note: NIACL, GODIGIT, NIVABUPA ratios use FY2025 estimates from available data; ROE/loss ratio not available for all peers. GWP for NIACL, GODIGIT, NIVABUPA in FY2025 crore.
Key peer observations:
Star Health's P/GWP of 1.64× sits between the PSU discount (NIACL at 0.59×) and the ICICI Lombard premium (3.35×). This positioning reflects the market's view that Star Health is a high-quality private insurer with a superior retail franchise, but not yet earning the premium returns that would justify ICICI Lombard-level multiples. Niva Bupa (second-largest SAHI, listed Nov 2024) at 2.22× P/GWP is trading at a premium to Star Health despite being smaller and less profitable — suggesting the market assigns a discovery premium to the newer listing that may not persist. New India Assurance at 0.59× P/GWP is the classic PSU discount; Star Health will always deserve a premium to PSU peers given its retail focus, private management, and higher growth potential. The most relevant comparison is ICICI Lombard, which earns consistently higher ROE (~18%+) through diversified lines and superior claims management, justifying its 3.35× P/GWP premium.
8. What to Watch in the Financials
What the financials confirm: Star Health is a structurally sound insurer with 20%+ annual GWP growth since FY2018, a dominant 31% retail health market share, a stable ~8% investment yield on a ₹17,898 crore portfolio, and a solvency ratio well above the regulatory floor. The FY2026 combined ratio improvement to 98.8% (with Q4 at 95.7%) is the most credible post-COVID signal that the underwriting engine can deliver sustained profitability.
What the financials contradict: The current P/B of 4.0× is priced for a company earning 20%+ ROE. Statutory ROE was only 7.6% in FY2026 and 9.2% in FY2025 — far below what the valuation requires. Even the IndAS ROE of 12.5% falls short of the implied target. Book value compounding at ~8% per year while the stock trades at 4× book means the stock's return in a flat-valuation scenario is roughly 8% — roughly in line with the cost of equity and far below what investors paid at the IPO.
What to watch next: The monsoon quarter (Q1 FY2027, results expected ~July 2026) will test whether the Q4 FY2026 combined ratio improvement of 95.7% is durable or seasonal. In Q1 FY2026, the combined ratio was 102.1%. A reading below 100% in Q1 FY2027 would be a genuine regime change. A reversion to 102%+ would signal the claims cycle is not yet tamed.
The first financial metric to watch is the Q1 FY2027 combined ratio — if it holds below 100% through the highest-claims quarter of the year, the path to sustainable 15%+ ROE and a defensible 3–4× P/B becomes plausible. If it reverts above 102%, the valuation premium is difficult to justify at current book multiples.